Fluphenazine

Introduction Overview

Generic Name

fluphenazine

Brand Name

Permitil, Prolixin, Prolixin Decanoate, Prolixin Enanthate

Dosage Form

oral tablet, oral concentrate, oral elixir, injectable solution, injectable decanoate

Drug Class

Phenothiazine antipsychotics

Pharmacokinetics

Absorption:
Fluphenazine is well absorbed following oral administration, with onset of action typically observed within hours. Oral formulations include tablets, elixirs, and concentrates, each allowing for tailored absorption kinetics. After intramuscular injection, particularly with the decanoate form, absorption is slow and sustained due to depot formation at the injection site, leading to prolonged drug release over weeks. The bioavailability after oral dosing can be variable due to first-pass hepatic metabolism. Food intake does not significantly affect absorption, but care is needed when switching between formulations due to differing pharmacokinetics.

Distribution:
Fluphenazine is highly lipophilic and extensively distributed in body tissues, including the central nervous system, which facilitates its therapeutic effects in psychotic disorders. It is approximately 90-95% bound to plasma proteins, primarily albumin, which influences its free active concentration. The volume of distribution is large, signifying deep tissue penetration. It crosses the blood-brain barrier efficiently, as well as the placenta and is excreted in breast milk, necessitating careful use in pregnancy and lactation.

Metabolism:
Hepatic metabolism of fluphenazine is predominantly via the cytochrome P450 enzyme system, including CYP2D6 and CYP1A2 isoforms, through processes such as hydroxylation and demethylation. The drug undergoes first-pass metabolism significantly after oral administration, resulting in various active and inactive metabolites. Metabolic rate may be affected by genetic polymorphisms, liver function status, and the presence of concomitant drugs that induce or inhibit hepatic enzymes, thus impacting plasma levels and clinical response.

Elimination:
Elimination of fluphenazine and its metabolites occurs primarily via renal excretion, with a smaller proportion eliminated in feces. The half-life varies depending on the formulation: oral fluphenazine has a half-life of approximately 15-30 hours, whereas the decanoate injectable form exhibits a much longer half-life of up to several days to weeks due to slow release from the depot. Steady-state levels are achieved more slowly with depot formulations. Dosing intervals are adjusted accordingly. Impaired renal or hepatic function can prolong elimination and necessitate dosage adjustments.

Dosage Forms

Available Dosage Forms:
- Oral tablets: 1 mg, 2.5 mg, 5 mg, 10 mg
- Oral concentrate solution: 5 mg/mL
- Oral elixir: 2.5 mg/5 mL
- Injectable solution: 2.5 mg/mL
- Injectable decanoate solution: 25 mg/mL

Dosages for Adults and Adolescents:
- Oral administration (psychosis):
- Initial dose: 2.5 to 10 mg per day divided into doses every 6 to 8 hours
- Maintenance dose: 1 to 5 mg per day, may be given as a single daily dose
- Maximum dose: Up to 40 mg per day
- Parenteral administration:
- Fluphenazine hydrochloride injection:
- Initial dose: 2.5 to 10 mg intramuscularly, divided every 6 to 8 hours
- Maximum dose: 10 mg per day
- Fluphenazine decanoate injection (for long-term maintenance):
- Initial dose: 12.5 to 25 mg deep intramuscular gluteal injection
- Maintenance dose: 12.5 to 100 mg every 3 to 4 weeks
- Maximum dose: 100 mg per injection

Specific Patient Populations:
- Geriatric patients:
- Lower initial dose recommended at 1 to 2.5 mg orally divided every 6 to 8 hours
- Maintenance doses similar to adults but titrated carefully with maximum dose up to 40 mg per day
- May require slower titration due to increased sensitivity
- Pediatric use:
- Not approved for use in children under 12 years old
- Use in adolescents requires cautious dosing and monitoring
- Patients with hepatic or renal impairment:
- Dosing adjustments recommended due to altered metabolism and elimination
- Close monitoring for toxicity and side effects advised
- Administration Notes:
- Oral concentrate must be diluted with at least 2 ounces of liquid such as milk, tomato or fruit juice (excluding apple juice), or caffeine-free soft drink before administration
- Injectable decanoate formulation is administered by healthcare professionals at infrequent intervals due to prolonged depot effect
- Switching between oral and injectable forms requires dosage recalibration (oral dose ~2-3 times injection dose)

Mechanism Of Action

Fluphenazine is a classic phenothiazine antipsychotic that primarily exerts its therapeutic effects through potent antagonism of dopamine D2 receptors in the brain. By binding to and blocking postsynaptic D2 receptors in the mesolimbic and mesocortical pathways, fluphenazine modulates dopaminergic neurotransmission implicated in the pathophysiology of schizophrenia and other psychotic disorders. This receptor blockade reduces positive symptoms such as hallucinations and delusions.

At the cellular level, fluphenazine stabilizes neuronal membranes by inhibiting dopamine-mediated signal transduction pathways. It also exerts some affinity for other neurotransmitter receptors including adrenergic (alpha-1), histaminergic (H1), and muscarinic cholinergic receptors, contributing to its side effect profile. The drug's inhibition of these receptors can also modulate mood, cognition, and autonomic functions to some extent.

Biochemically, fluphenazine interferes with dopamine synthesis and release, and may alter intracellular signaling cascades downstream of dopamine receptor activation. The drug's high lipophilicity facilitates its accumulation in central nervous system tissues ensuring effective receptor occupancy. Long-acting depot formulations provide sustained receptor blockade, aiding adherence and symptom stabilization in chronic psychosis.

Clinically, the mechanism of action translates to effective management of schizophrenia manifestations, including diminished psychotic episodes and improved functional outcomes. Compared to atypical antipsychotics, fluphenazine is associated with a higher risk of extrapyramidal side effects due to stronger D2 receptor antagonism. Research and clinical trials have established its efficacy over decades, although newer agents with broader receptor profiles offer alternative therapeutic options.

Pharmacological Actions

Potent antagonism of dopamine D2 receptors in the central nervous system
Modulation of dopaminergic neurotransmission to reduce psychotic symptoms
Antagonism at alpha-1 adrenergic receptors causing vasodilation and orthostatic hypotension
Histamine H1 receptor blockade contributing to sedation and weight gain
Muscarinic receptor antagonism leading to anticholinergic side effects such as dry mouth
Stabilization of neuronal membranes reducing abnormal excitability
Reduction of positive symptoms of schizophrenia including hallucinations and delusions
Exhibits antipsychotic effects with a relatively higher incidence of extrapyramidal symptoms
Extended dopamine receptor blockade with depot formulations allowing sustained symptom control
Minimal effect on serotonin receptors compared to atypical antipsychotics
Potential suppression of nausea and vomiting through dopamine receptor blockade in the chemoreceptor trigger zone
Modulation of neurotransmitter pathways influencing mood and behavior
Inhibition of dopamine-mediated intracellular signaling leading to decreased neuronal firing

Therapeutic Or Clinical Uses

Management and treatment of schizophrenia and related psychotic disorders
Control of acute and chronic manifestations of psychosis including hallucinations and delusions
Use in patients requiring prolonged parenteral neuroleptic therapy, especially those with chronic schizophrenia
Off-label uses include treatment of severe agitation and psychotic symptoms in other mental health conditions
Maintenance therapy to prevent relapse in patients stabilized on oral or injectable forms
Adjunctive treatment in management of schizoaffective disorder
Used when patients exhibit poor adherence to oral medication via long-acting depot injections
Management of refractory psychotic symptoms when other antipsychotics are ineffective
Symptomatic control of nausea and vomiting not responsive to conventional antiemetics (off-label)
Treatment of psychosis-associated behavioral disturbances in hospital or institutional settings
Where rapid control of severe psychotic agitation is required, injectable formulation preferred
Long-term management in clinically stable patients to improve quality of life
May aid in reducing suicidal ideation related to psychotic disorders
Limited use in dementia-related psychosis is contraindicated due to increased mortality risk

Side Or Adverse Effects

Extrapyramidal symptoms such as dystonia, akathisia, Parkinsonism, and tardive dyskinesia
Sedation and drowsiness impacting daily activities
Orthostatic hypotension causing dizziness especially on standing
Anticholinergic effects including dry mouth, constipation, urinary retention, and blurred vision
Neuroleptic malignant syndrome, a rare but potentially fatal condition
Weight gain and metabolic alterations contributing to increased cardiovascular risk
Breast swelling or tenderness due to hyperprolactinemia
Impotence and sexual dysfunction including difficulty achieving orgasm
Seizures, particularly in patients with seizure disorder history
Low white blood cell counts (leukopenia or agranulocytosis), increasing infection risk
Jaundice reflecting possible hepatotoxicity
Constipation and gastrointestinal discomfort
Increased sweating and nasal congestion
Photosensitivity reactions with increased risk of sunburn
Rare serious skin reactions such as Stevens-Johnson syndrome

Precautions

Use with caution in patients with history of liver or kidney impairment
Avoid abrupt discontinuation to prevent withdrawal and symptom relapse
Cautious use in patients with pre-existing heart problems or arrhythmias
Monitor closely in patients with low white blood cell counts or blood dyscrasias
Adjust dosing carefully in elderly patients due to enhanced sensitivity
Obtain baseline and periodic liver function tests during prolonged therapy
Avoid use in patients with brain damage or severe depression
Use caution in patients with glaucoma due to anticholinergic effects
Careful monitoring required in patients with seizure disorders
Avoid concurrent use with alcohol or other CNS depressants
Be vigilant for early signs of neuroleptic malignant syndrome or tardive dyskinesia
Warn patients regarding the risk of dizziness and fall hazards
Educate patients about photosensitivity and sun exposure precautions
Pregnancy and breastfeeding require risk-benefit assessment due to potential neonatal effects
Caution if exposure to extreme temperatures or insecticides is anticipated

Warnings

Not approved for treatment of dementia-related psychosis due to increased mortality risk
Risk of developing potentially irreversible tardive dyskinesia with prolonged use and high doses
Severe movement disorders may develop, especially in elderly or vulnerable patients
May cause severe hypersensitivity reactions including anaphylaxis
Risk of neuroleptic malignant syndrome characterized by hyperthermia and rigidity
Can precipitate or worsen depression and suicidal ideation in susceptible individuals
Use contraindicated in patients with liver disease, brain damage, or blood cell disorders
Avoid use with large amounts of alcohol or CNS depressants due to additive sedation
Potential for severe orthostatic hypotension leading to falls and injury
Use during late pregnancy may result in newborn respiratory depression or withdrawal symptoms
Emergency medical attention required for symptoms of uncontrolled muscle movements
May falsely alter pregnancy test results
Dose adjustments required when switching between oral and injectable formulations
Proper storage recommended to maintain drug stability and efficacy
Close monitoring advised when co-administered with other QT-prolonging agents

Contraindication

Known hypersensitivity to fluphenazine or other phenothiazine derivatives
Severe liver disease or significant hepatic impairment
Pre-existing blood dyscrasias including low platelet, red or white blood cell counts
History of brain damage or severe central nervous system depression
Severe depressive states where neuroleptics may exacerbate symptoms
Concurrent use with central nervous system depressants or excessive alcohol
Patients with uncontrolled seizure disorders not adequately managed
Known hypersensitivity to injectable components such as benzyl alcohol
Children younger than 12 years since safety and efficacy not established
Use in patients with pheochromocytoma without appropriate monitoring
Patients with narrow-angle glaucoma due to anticholinergic potential
Patients with Parkinson’s disease may experience worsening of symptoms
Contraindicated in any patient demonstrating neuroleptic malignant syndrome
Patients exhibiting drug-induced bone marrow suppression
Known QT interval prolongation or cardiac arrhythmias without cardiology clearance

Drug Interactions

Concurrent use with CNS depressants (opioids, benzodiazepines, alcohol) increases sedation
Additive risk of extrapyramidal symptoms when combined with other dopamine antagonists
Enzyme inhibitors like CYP2D6 inhibitors (e.g., fluoxetine) may increase fluphenazine plasma levels
Enzyme inducers such as carbamazepine may reduce therapeutic effect by increasing metabolism
Antihypertensive agents may potentiate orthostatic hypotension caused by fluphenazine
Drugs prolonging QT interval may increase risk of cardiac arrhythmias
Concomitant use with anticholinergic drugs can exacerbate anticholinergic side effects
Interaction with Parkinson’s disease medications that increase dopamine may diminish efficacy
Use with lithium can increase neurotoxicity risk
Potential interference with dopamine agonist therapies for restless leg syndrome or prolactinomas
Co-administration with digoxin may require monitoring due to altered cardiac function
Concurrent treatment with CYP1A2 inducers like smoking may reduce plasma levels
Combination with other neuroleptics increases risk of adverse neurological effects
May reduce effectiveness of hormonal contraceptives due to cytochrome P450 interactions
Additive hypotensive effects when combined with nitrates or other vasodilators

Preparations Of The Drug

Oral tablets available in strengths of 1 mg, 2.5 mg, 5 mg, and 10 mg for flexible dosing
Oral concentrate solution at 5 mg/mL requiring dilution before administration
Oral elixir providing 2.5 mg/5 mL for patients with swallowing difficulties or dose flexibility
Injectable aqueous solution (2.5 mg/mL) for rapid symptom control via intramuscular or subcutaneous administration
Long-acting injectable decanoate formulation (25 mg/mL) administered intramuscularly for maintenance therapy
All injectable forms require healthcare professional administration and monitoring
Tablet and oral liquid forms designed to allow dosing adjustments tailored to patient needs
Packaging includes dosing syringes and detailed patient instructions to ensure accurate administration
Stable at room temperature, protected from moisture and light to maintain potency
Oral concentrate must be mixed with appropriate liquids like milk or juice except apple juice to ensure bioavailability
Depot injections designed to release drug slowly over 3 to 4 weeks, enhancing adherence
Manufactured under strict pharmaceutical guidelines to ensure consistency in bioavailability
Fluphenazine preparations are available under multiple brand names facilitating options for prescribers
All formulations require careful handling to avoid exposure and ensure patient safety
Patient education materials accompany most commercial preparations to inform on proper use and side effect management